866-997-4948(US-Canada Toll Free)

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : 73 Pages

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2017

Summary

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Cancer/Testis Antigen 1 is a protein encoded by CTAG1A gene is an antigen that is over expressed in many cancers but that is also expressed in normal ovary and testis tissues which makes it a good candidate for a cancer vaccine.

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 6 and 4 respectively. Similarly, the universities portfolio in Phase I stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Fallopian Tube Cancer, Metastatic Melanoma, Soft Tissue Sarcoma, Lung Cancer, Metastatic Ovarian Cancer, Synovial Sarcoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Melanoma, Metastatic Breast Cancer, Myelodysplastic Syndrome, Ovarian Cancer, Peritoneal Cancer, Prostate Cancer, Advanced Malignancy, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Bladder Cancer, Ewing Sarcoma, Head And Neck Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Kidney Cancer (Renal Cell Cancer), Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Myxoid Liposarcoma, Neuroblastoma, Oligodendroglioma, Osteosarcoma, Rhabdomyosarcoma, Round Cell Liposarcoma, Sarcomas, Solid Tumor, Transitional Cell Cancer (Urothelial Cell Cancer) and Uterine Cancer.

The latest report CancerTestis Antigen 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)
- The report reviews Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Overview 7
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 14
Products under Development by Universities/Institutes 19
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Therapeutics Assessment 21
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Companies Involved in Therapeutics Development 25
Boehringer Ingelheim GmbH 25
Celldex Therapeutics Inc 26
GlaxoSmithKline Plc 27
Immune Design Corp 28
ImmunoFrontier Inc 29
Sanofi Pasteur SA 29
Scancell Holdings Plc 30
Vault Pharma Inc 30
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Drug Profiles 31
BI-1361849 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
CDX-1401 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
CMB-305 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
CMB-305 + G-100 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
CUE-102 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
CYN-101 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
G-305 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
GSK-2241658A - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
IMF-001 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
IMM-65 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
LV-305 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
SCIB-2 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
VCP-2292 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
VPI-111 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Dormant Products 56
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Discontinued Products 59
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Product Development Milestones 60
Featured News & Press Releases 60
Jun 26, 2017: Scancell Holdings Announces SCIB-2 Patent Granted in Europe 60
Jun 05, 2017: Immune Design Updates Positive Data from Lead Cancer Immunotherapy Program CMB305 at ASCO Annual Meeting 60
Jun 01, 2017: Immune responses from early study of novel sarcoma vaccine 62
May 17, 2017: New Clinical and Biomarker Data Validate Immune Design's CMB305 Program 63
Dec 05, 2016: Celldex Presents Data on CDX-1401 at the American Society of Hematology Annual Meeting 64
Oct 10, 2016: Scancell preparing SCIB2 for clinical study in lung cancer 64
Jun 08, 2016: Immune Design Announces Updated Results For Its Immuno-oncology Product Candidate LV305 at ASCO 65
Jun 08, 2016: Immune Design Announces Updated Results For Immuno-oncology Product Candidate CMB305 At ASCO 66
Jun 04, 2016: Celldex Therapeutics' CDX-1401, CDX-301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma 66
Apr 21, 2016: Immune Design Announces Presentation on LV-305 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 68
Apr 18, 2016: Celldex Therapeutics Presents Poster on CDX-1401 at the AACR Annual Meeting 2016 68
Feb 09, 2016: Immune Design Announces Positive Topline Data From Phase 1 Clinical Trial of CMB305 69
Jan 08, 2016: Immune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305 69
Nov 11, 2015: Immune Design Announces Start of Randomized Phase 2 Cancer Immunotherapy Combination Trial in Patients with Soft Tissue Sarcoma 70
Aug 12, 2015: Immune Design Announces Phase 2 Cancer Immunotherapy Trial Collaboration 70
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 72
Disclaimer 73

List of Tables
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indications, H2 2017 11
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 13
Number of Products under Development by Companies, H2 2017 14
Products under Development by Companies, H2 2017 15
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 17
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 18
Number of Products under Investigation by Universities/Institutes, H2 2017 19
Products under Investigation by Universities/Institutes, H2 2017 20
Number of Products by Stage and Route of Administration, H2 2017 22
Number of Products by Stage and Molecule Type, H2 2017 24
Pipeline by Boehringer Ingelheim GmbH, H2 2017 25
Pipeline by Celldex Therapeutics Inc, H2 2017 26
Pipeline by GlaxoSmithKline Plc, H2 2017 27
Pipeline by Immune Design Corp, H2 2017 28
Pipeline by ImmunoFrontier Inc, H2 2017 29
Pipeline by Sanofi Pasteur SA, H2 2017 29
Pipeline by Scancell Holdings Plc, H2 2017 30
Pipeline by Vault Pharma Inc, H2 2017 30
Dormant Products, H2 2017 56
Dormant Products, H2 2017 (Contd..1), H2 2017 57
Dormant Products, H2 2017 (Contd..2), H2 2017 58
Discontinued Products, H2 2017 59

List of Figures
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 10
Number of Products by Routes of Administration, H2 2017 21
Number of Products by Stage and Routes of Administration, H2 2017 21
Number of Products by Molecule Types, H2 2017 23
Number of Products by Stage and Molecule Types, H2 2017 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *